European Journal of Heart Failure最新文献_第6页

Long-term exposure to fine particulate matter constituents, genetic susceptibility, and incident heart failure among 411 807 adults. 411 807 名成年人长期暴露于细颗粒物成分、遗传易感性和心力衰竭事件。

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-22 DOI: 10.1002/ejhf.3486

Feipeng Cui,Lei Zheng,Jing Zhang,Linxi Tang,Yudiyang Ma,Dankang Li,Jianing Wang,Meiqi Xing,Junqing Xie,Jian Yang,Yaohua Tian

{"title":"Long-term exposure to fine particulate matter constituents, genetic susceptibility, and incident heart failure among 411 807 adults.","authors":"Feipeng Cui,Lei Zheng,Jing Zhang,Linxi Tang,Yudiyang Ma,Dankang Li,Jianing Wang,Meiqi Xing,Junqing Xie,Jian Yang,Yaohua Tian","doi":"10.1002/ejhf.3486","DOIUrl":"https://doi.org/10.1002/ejhf.3486","url":null,"abstract":"AIMSLong-term fine particulate matter (PM2.5) exposure has been linked to incident heart failure (HF), but the impacts of its constituents remain unknown. We aimed to investigate the associations of PM2.5 constituents with incident HF, and further evaluate the modification effects of genetic susceptibility.METHODS AND RESULTSPM2.5 and its constituents, including elemental carbon (EC), organic matter (OM), ammonium (NH4 +), nitrate (NO3 -), and sulfate (SO4 2-), were estimated using the European Monitoring and Evaluation Programme model applied to the UK (EMEP4UK) driven by Weather and Research Forecast model meteorology. A polygenic risk score (PRS) was calculated to represent genetic susceptibility to HF. We employed Cox models to evaluate the associations of PM2.5 constituents with incident HF. Quantile-based g-computation model was used to identify the main contributor of PM2.5 constituents. Among 411 807 individuals in the UK Biobank, 7554 participants developed HF during a median follow-up of 12.05 years. The adjusted hazard ratios of HF for each interquartile range increase in PM2.5, EC, OM, NH4 +, NO3 -, and SO4 2- were 1.50 (1.46-1.54), 1.31 (1.27-1.34), 1.12 (1.09-1.15), 1.42 (1.41-1.44), 1.26 (1.23-1.29), and 1.25 (1.24-1.26), respectively. EC (43%) played the most important role, followed by NH4 + and SO4 2-. Moreover, synergistic additive interactions accounted for 9-16% of the HF events in individuals exposed to both PM2.5, NH4 +, NO3 -, and SO4 2- and PRS.CONCLUSIONLong-term exposure to PM2.5 constituents may elevate HF risk, and EC was the major contributor. Additive effects of PM2.5 constituents and PRS on HF risk were revealed.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"14 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A clinical classification method with outstanding advantages for quickly identifying hazardous types 一种临床分类方法，在快速识别危险类型方面具有突出优势

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-18 DOI: 10.1002/ejhf.3479

Lanxin Zhu, Jingnan Liu, Huihui Zhao

引用次数: 0

Microvascular obstruction in cardiac amyloidosis 心脏淀粉样变性中的微血管阻塞

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-18 DOI: 10.1002/ejhf.3481

Lucrezia Netti, Adam Ioannou, Ana Martinez-Naharro, Yousuf Razvi, Aldostefano Porcari, Lucia Venneri, Viviana Maestrini, Dan Knight, Ruta Virsinskaite, Muhammad U. Rauf, Tushar Kotecha, Rishi K. Patel, Ashutosh Wechelakar, Helen Lachmann, Peter Kellman, Charlotte Manisty, James Moon, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana

引用次数: 0

Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’ 对 "一种具有突出优势的临床分类方法，可快速识别危险类型 "的答复

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-18 DOI: 10.1002/ejhf.3480

Ovidiu Chioncel

引用次数: 0

What's new in heart failure? October 2024 心力衰竭有何新进展？2024 年 10 月

IF 16.9 1区医学

European Journal of Heart Failure Pub Date : 2024-10-14 DOI: 10.1002/ejhf.3492

Matthew M.Y. Lee, Pau Codina, Daniela Tomasoni, Alberto Aimo

引用次数: 0

Risk scoring in pulmonary hypertension: One size fits all? 肺动脉高压的风险评分：一刀切？

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-09 DOI: 10.1002/ejhf.3459

Irene M. Lang, Vladimir Gojic

引用次数: 0

Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial 根据射血分数评估 2 型糖尿病患者使用艾塞那肽治疗心血管疾病的效果：EXSCEL试验

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-09 DOI: 10.1002/ejhf.3478

João Sérgio Neves, Ana Rita Leite, Robert J. Mentz, Rury R. Holman, Faiez Zannad, Javed Butler, Milton Packer, João Pedro Ferreira

引用次数: 0

Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. 心力衰竭住院后使用托塞米和呋塞米的利尿剂剂量和疗效：TRANSFORM-HF 试验。

IF 16.9 1区医学

European Journal of Heart Failure Pub Date : 2024-10-04 DOI: 10.1002/ejhf.3458

Nina Nouhravesh, Stephen J Greene, Robert Clare, Daniel Wojdyla, Kevin J Anstrom, Eric Velazquez, Bertram Pitt, Robert J Mentz, Mitchell A Psotka

{"title":"Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.","authors":"Nina Nouhravesh, Stephen J Greene, Robert Clare, Daniel Wojdyla, Kevin J Anstrom, Eric Velazquez, Bertram Pitt, Robert J Mentz, Mitchell A Psotka","doi":"10.1002/ejhf.3458","DOIUrl":"10.1002/ejhf.3458","url":null,"abstract":"Aims: The TRANSFORM-HF trial found no difference in clinical outcomes between torsemide versus furosemide after hospitalization for heart failure. This analysis aimed to assess the impact of diuretic dosing on the primary and secondary clinical outcomes.Methods and results: This post-hoc analysis of TRANSFORM-HF categorized patients into three groups by discharge diuretic dose: (1) ≤40 mg, (2) >40-80 mg, and (3) >80 mg of furosemide equivalents. The associations between discharge dose and 12-month clinical events, and change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), were assessed. Overall, 2379 patients were included, aged 65 years (interquartile range 56-75), 883 (37.1%) women, and 812 (34.2%) Black. Furosemide had adjusted hazard ratios (aHR) for all-cause mortality of 1.21 (95% confidence interval [CI] 0.91-1.59) for discharge dose group 2 and 1.40 (95% CI 1.04-1.88) for group 3, compared with group 1. For torsemide, aHRs were 1.74 (95% CI 1.32-2.30) for group 2 and 1.58 (95% CI 1.14-2.19) for group 3. No evidence of heterogeneity for the association between increased mortality and higher dose was found by loop diuretic type (pinteraction = 0.17). Higher doses of furosemide and torsemide were associated with increased risk of all-cause hospitalization and the composite of all-cause mortality and hospitalization, without evidence of heterogeneity by loop diuretic type (pinteraction > 0.2). Changes in KCCQ-CSS from baseline at 12 months was similar across dose groups for both drugs.Conclusion: Following hospitalization for heart failure, higher loop diuretic dosing was independently associated with worse clinical and patient-reported outcomes. The correlation between higher loop diuretic dose and outcomes was consistent, regardless of loop diuretic used.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing congestive heart failure: It is mostly about water, not salt! 控制充血性心力衰竭：主要是水，而不是盐！

IF 16.9 1区医学

European Journal of Heart Failure Pub Date : 2024-10-03 DOI: 10.1002/ejhf.3457

Antonio Iaconelli, Insa Emrich, Pierpaolo Pellicori, John G F Cleland

引用次数: 0

Multicentre, randomized, double-blind, prospective study on the effects of ImmunoAdSorptiOn on cardiac function in patients with Dilated CardioMyopathy (IASO-DCM): Rationale and design. 多中心、随机、双盲、前瞻性研究：ImmunoAdSorptiOn 对扩张型心肌病患者心脏功能的影响 (IASO-DCM)：原理与设计。

IF 16.9 1区医学

European Journal of Heart Failure Pub Date : 2024-10-02 DOI: 10.1002/ejhf.3476

Marcus Dörr, Michael Böhm, Erland Erdmann, Stefan Groß, Amir-Abbas Mahabadi, Matthias Nauck, Georg Nickening, Heinz-Peter Schultheiss, Alexander Staudt, Karl Werdan, Finn Waagstein, Åke Hjalmarson, Stephan B Felix

{"title":"Multicentre, randomized, double-blind, prospective study on the effects of ImmunoAdSorptiOn on cardiac function in patients with Dilated CardioMyopathy (IASO-DCM): Rationale and design.","authors":"Marcus Dörr, Michael Böhm, Erland Erdmann, Stefan Groß, Amir-Abbas Mahabadi, Matthias Nauck, Georg Nickening, Heinz-Peter Schultheiss, Alexander Staudt, Karl Werdan, Finn Waagstein, Åke Hjalmarson, Stephan B Felix","doi":"10.1002/ejhf.3476","DOIUrl":"https://doi.org/10.1002/ejhf.3476","url":null,"abstract":"Aims: Pilot studies indicate that immunoadsorption with subsequent IgG substitution (IA/IgG) induces beneficial effects in patients with dilated cardiomyopathy (DCM) and heart failure. This placebo-controlled study investigates whether IA/IgG treatment enhances left ventricular (LV) systolic function as compared to a control group receiving pseudo-treatment.Methods: This multicentre, randomized, double-blind, parallel-group trial aims to include 200 patients with heart failure due to DCM (LV ejection fraction [LVEF] <40%) on optimized guideline-directed heart failure medication. Participants are randomly assigned in a 1:1 ratio to IA/IgG using protein-A columns, or to pseudo-immunoadsorption followed by an intravenous infusion without IgG. Follow-up visits take place by telephone after 1 and 3 months and at the study centres after 6, 12 and 24 months. The primary efficacy endpoint is the change in LVEF from baseline to 6 months determined by contrast echocardiography, analysed at a core lab. In addition, LV end-diastolic and end-systolic volumes will be analysed as secondary endpoints over the entire study period to assess whether IA/IgG affects LV remodelling. As main secondary outcome, a composite of all-cause death, cardiac resuscitation, hospitalization for heart failure, and need for cardiac surgery to improve myocardial pump function will be evaluated after 24 months. In addition, exploratory outcomes as well as safety endpoints related to the treatment will be assessed throughout the whole study period.Conclusion: IASO-DCM is a randomized study which will provide comprehensive insights into the effects of immunoadsorption with subsequent IgG substitution in patients with DCM.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142363605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0